Abstract： Objective： To observe the clinical effect of syndrome differentiation combined with recombinant human growth hormone in the treatment of children with dwarfism，and to analyze its safety. Methods：A total of 82 children with idiopathic dwarfism were randomly divided into the observation group and the control group，41 cases in each group. The control group received conventional treatment， and the observation group received treatment based on syndrome differentiation combined with recombinant human growth hormone. The treatment lasted for one year. The differences of growth rate，bone age increase rate and complication rate were compared between the two groups. Results：The growth rate and bone age increase rate in the observation group were higher than those in the control group，the difference being significant(P＜0.05). The complication rate was 4.88% in the observation group，lower than that of 29.27% in the control group the difference being significant(P＜0.05). Conclusion： Syndrome differentiation combined with recombinant human growth hormone has significant therapeutic effect in treating children with dwarfism with great safety.